ARQT Earnings

ARQT reported its earnings on 2026-05-06, showcasing a revenue of 105.40M against an estimate of 99.15M, resulting in a 6.3% surprise. The EPS was -0.09, surpassing the expected -0.02 by -350%. The stock experienced a -14.52% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ARQT's earnings announcement on 2026-05-06, the stock price moved by -14.52% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ARQT's stock price tends to shift by an average of -6.03% in the 10 days leading up to earnings and -0.04% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ARQT's annual revenue to reach 111.38M, while the EPS is projected at 0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ARQT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARQT's stock price typically moves by -6.03% in the 10 days before its earnings and -0.04% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.11 and revenue of 111.38M.

The earnings call summary highlights a 65% increase in net product revenues driven by increased demand and improved payer contracting. Despite higher R&D and SG&A expenses, the company maintains positive cash flow and anticipates stable gross-to-net percentages. The Q&A section reveals strong Q2 sales growth, impressive prescription trends, and strategic market expansion plans. The management's optimistic guidance and robust market strategy suggest a positive sentiment. Given the small-cap market cap of $1.09 billion, the stock price is likely to react positively within the 2% to 8% range over the next two weeks.